Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Filter results: >>>>

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC1806	TGX221	1	72	flat	flat	HCC1806 TGX-221 0 1 72	8	2.679	Inf	1.0	-0.0118	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	1.0	0.01	-1.16	1.0	1.02
HCC1806	TGX221	2	72	flat	flat	HCC1806 TGX-221 0 2 72	8	2.763	Inf	1.0	-0.0114	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	1.0	0.01	-1.16	1.0	1.02
BT-20	Sirolimus	1	72	flat	flat	BT20 rapamycin 0 1 72	8	2.100	Inf	0.568	0.431	0.568	0.01	-9.89	1.0	0.568	Inf	0.6	0.601	0.6	0.01	-13.0	1.0	0.6
Hs 578T	Sirolimus	3		flat	flat	Hs578T rapamycin 3	8	2.836	Inf	0.675	0.309	0.675	0.01	-1.79	1.0	0.691	Inf	0.604	0.621	0.604	0.01	-3.02	1.0	0.621
BT-20	Sirolimus	3	72	flat	flat	BT20 rapamycin 0 3 72	8	2.661	Inf	0.54	0.46	0.54	0.01	NA	NA	0.54	Inf	0.499	0.499	0.499	0.01	NA	NA	0.499
BT-20	Sirolimus	2	72	flat	flat	BT20 rapamycin 0 2 72	8	1.952	Inf	0.421	0.579	0.421	0.01	NA	NA	0.421	Inf	0.513	0.513	0.513	0.01	NA	NA	0.513
BT-20	Everolimus	2	72	flat	flat	BT20 everolimus 0 2 72	8	1.785	Inf	0.426	0.574	0.426	0.01	NA	NA	0.426	Inf	0.547	0.547	0.547	0.01	NA	NA	0.547